MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma

Hanne Due(Aalborg University Hospital), Karen Dybkær(Aalborg University Hospital), Ken H. Young(Duke Medical Center), Laura Barrett Ryø(Aarhus University), Anna A. Schönherz(Aalborg University Hospital), Maria Nascimento Primo(Aarhus University), Min Xiao(Tongji Hospital), Emil Aagaard Thomsen(Aarhus University), Martin Bøgsted(Chr. Hansen (Denmark)), Jacob Giehm Mikkelsen(Aarhus University), Xiaohong Tan(Beijing Proteome Research Center), Ditte Starberg Jespersen(Aalborg University Hospital), Yuyang Pang(The University of Texas MD Anderson Cancer Center), Anne Stidholt Roug(Aalborg University Hospital)
Blood Advances
April 9, 2019
10.1182/bloodadvances.2018029660
Cited by 34

Related Papers

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
|Nature Medicine|2008|1.3k
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
|Blood|2017|429
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma
|Journal of Clinical Oncology|2015|418